A phase III study on CC-486 as maintenance therapy in patients with newly diagnosed acute myeloid leukemia found statistically significant and clinically meaningful improvement in overall survival compared to placebo.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe